Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine

Alan P. Kozikowski, Kenneth M. Johnson, Olivier Deschaux, Bidhan C. Bandyopadhyay, Gian Luca Araldi, Gilberto Carmona, Patrik Munzar, Miles P. Smith, Robert L. Balster, Patrick M. Beardsley, Srihari R. Tella

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like "agonist" and some cocaine "antagonist" properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume305
Issue number1
DOIs
StatePublished - Apr 1 2003

Fingerprint

Cocaine
methyl 4-(4-chlorophenyl)-1-methylpiperidine-3-carboxylate
piperidine
N-cyclopropyl adenosine-5'-carboxamide
Pharmacology
Cocaine-Related Disorders
Self Administration
Carboxylic Acids
Macaca mulatta
Pharmaceutical Preparations
Rodentia
Dopamine
Serotonin
Norepinephrine
Seizures

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine. / Kozikowski, Alan P.; Johnson, Kenneth M.; Deschaux, Olivier; Bandyopadhyay, Bidhan C.; Araldi, Gian Luca; Carmona, Gilberto; Munzar, Patrik; Smith, Miles P.; Balster, Robert L.; Beardsley, Patrick M.; Tella, Srihari R.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 305, No. 1, 01.04.2003, p. 143-150.

Research output: Contribution to journalArticle

Kozikowski, AP, Johnson, KM, Deschaux, O, Bandyopadhyay, BC, Araldi, GL, Carmona, G, Munzar, P, Smith, MP, Balster, RL, Beardsley, PM & Tella, SR 2003, 'Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine', Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 1, pp. 143-150. https://doi.org/10.1124/jpet.102.046318
Kozikowski, Alan P. ; Johnson, Kenneth M. ; Deschaux, Olivier ; Bandyopadhyay, Bidhan C. ; Araldi, Gian Luca ; Carmona, Gilberto ; Munzar, Patrik ; Smith, Miles P. ; Balster, Robert L. ; Beardsley, Patrick M. ; Tella, Srihari R. / Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine. In: Journal of Pharmacology and Experimental Therapeutics. 2003 ; Vol. 305, No. 1. pp. 143-150.
@article{080ec4c0ff5240769bec1f278e55571f,
title = "Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine",
abstract = "The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like {"}agonist{"} and some cocaine {"}antagonist{"} properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.",
author = "Kozikowski, {Alan P.} and Johnson, {Kenneth M.} and Olivier Deschaux and Bandyopadhyay, {Bidhan C.} and Araldi, {Gian Luca} and Gilberto Carmona and Patrik Munzar and Smith, {Miles P.} and Balster, {Robert L.} and Beardsley, {Patrick M.} and Tella, {Srihari R.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1124/jpet.102.046318",
language = "English (US)",
volume = "305",
pages = "143--150",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine

AU - Kozikowski, Alan P.

AU - Johnson, Kenneth M.

AU - Deschaux, Olivier

AU - Bandyopadhyay, Bidhan C.

AU - Araldi, Gian Luca

AU - Carmona, Gilberto

AU - Munzar, Patrik

AU - Smith, Miles P.

AU - Balster, Robert L.

AU - Beardsley, Patrick M.

AU - Tella, Srihari R.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like "agonist" and some cocaine "antagonist" properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.

AB - The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like "agonist" and some cocaine "antagonist" properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.

UR - http://www.scopus.com/inward/record.url?scp=0037382399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037382399&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.046318

DO - 10.1124/jpet.102.046318

M3 - Article

C2 - 12649362

AN - SCOPUS:0037382399

VL - 305

SP - 143

EP - 150

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -